Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8343999 | Molecular Genetics and Metabolism | 2012 | 6 Pages |
Abstract
Children with Down syndrome (DS) often present with hematopoietic abnormalities, and are at increased risk of developing leukemia. Specifically, 3-10% of newborns with DS are diagnosed with transient myeloproliferative disease, and children with DS are 500 times more likely to develop acute megakaryoblastic leukemia (AMKL) and 20 times more likely to develop acute lymphoblastic leukemia (ALL) than typical children. This review examines the characteristics of these leukemias and their development in the unique genetic background of trisomy 21. A discussion is also provided for areas of future research and potential therapeutic development.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Laura Seewald, Jeffrey W. Taub, Kelly W. Maloney, Edward R.B. McCabe,